Full Press Release Details
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis.
REGN
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
Key Takeaway: FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis